News

Both the companies have jointly developed ARQ 092 by utlizing ArQule Kinase Inhibitor Platform (AKIP) technology, as per the agreement signed in November 2008. Daiichi Sankyo will retain

In the trial, patients with COPD were allowed to administer nebulized RPL554 as a single dose of 0.018 mg/kg. The study met its primary endpoint by showing that

Cloe PK facilitates drug discovery and agrochemical industries’ scientists to use ADME and physicochemical data to predict human and rodent pharmacokinetics. The prediction allows drugs to be ranked

A major ingredient in the product known as ‘indispensable biochemical partner of insulin,’ stimulates the activity of insulin, thereby helping in glucose and fat metabolism, besides breaking down

The solutions offered by the company will help meet basic, applied, and clinical research demands, providing unique in vitro assays. The company also supports research and development of

The multidisciplinary Symyx Notebook helps in moving therapeutic substances and related information from research through development to early manufacturing using efficient, validated and compliant processes. The notebook which

The Corning’s Board of Directors had approved around $40m capital expenditure plan for the project in July 2010. The facility, located in the Wujiang Economic Development Zone, features

As per the deal, AMRI will be the primary manufacturer and supplier of Rev7, AGC and other polymers present in Rev7 degradable gum products. The agreement will be

One patent has been awarded to the company’s Recall-Vax technology and the second patent has been granted for IN-N01. Recall-Vax is an active vaccine intended to generate highly